BRIEF

on RHÖN-KLINIKUM AG (ETR:RHK)

RHÖN-KLINIKUM AG Third Quarter 2026 Results

Stock price chart of RHÖN-KLINIKUM AG (EBR:RHK) showing fluctuations.

RHÖN-KLINIKUM AG reported robust financial results for the third quarter of 2026, showing resilience despite economic challenges. The company treated 8.3% more patients than the previous year, totaling 764,248, and achieved revenues of EUR 1,304 million. This growth is partly due to a 3.25% surcharge on hospital services introduced in 2026 to counter rising costs.

The company's strong equity ratio of 74.7% provides a stable base for optimizing healthcare structures. Key investments include a photon-counting CT at Universitätsklinikum Marburg and a new hybrid operating theatre in Frankfurt (Oder), both enhancing medical services and innovation.

Looking ahead, RHÖN-KLINIKUM expects revenues between EUR 1.7 billion ±5%, with EBITDA forecasted to reach EUR 110-125 million. Regulatory changes, such as the Hospital Reform Adjustment Act, present uncertainties for future operations amidst global economic volatility.

R. H.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all RHÖN-KLINIKUM AG news